TFF Pharmaceuticals gets European patent for particle technology

DPI developer TFF Pharmaceuticals has received a communication from the European Patent Office (EPO) in regards to its patent application No. 08771657.7 “Formation of Stable Submicron Peptide or Protein Particles by Thin Film Freezing,” giving notice of the EPO’s intention to grant a patent.

TFF Pharmaceuticals CEO Glenn Mattes commented, “We are very pleased to receive this notice regarding the first European patent for our thin film freezing technology. It will substantially expand the scope of our IP protection and further strengthen the company’s patent portfolio. We are in a strong proprietary position to develop our pipeline of unique dry powder formulations for innovative new pulmonary product solutions that address broad unmet drug delivery needs.”

Earlier this year, TFF Pharmaceuticals announced that it had licensed the TFF technology from the University of Texas at Austin and that the company had raised $14 million in Series A funding.

Read the TFF Pharmaceuticals press release.